NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
NovaBridge BiosciencesNASDAQ: NBP
Net Change in Cash · Q4 FY2025 · quarter ended Dec 2025
Net change in cash turns negative
Q4 FY2025 net change in cash was -$17.43M, compared with $0 a year earlier. Trailing-twelve-month net change in cash was $446.12M.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$17.43M or moves back toward the trailing-twelve-month quarterly average of $111.53M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
Mixed currencies · from the cash flow
- Latest · FY2025
- 142.37M USD
- Year-over-year change
- —
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 142.37M | — |
| FY2024 | 2024-12-31 | (1.71B) | -1025.6% |
| FY2023 | 2023-12-31 | (151.58M) | +28.8% |
| FY2022 | 2022-12-31 | (212.86M) | +82.8% |
| FY2021 | 2021-12-31 | (1.24B) | — |
Net Change in Cash vs competitors
How NBP compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥446.12M CNY | — | — | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $300.86M USD | — | +123.5% | — |
| LTM Mar 2026 | $78.09M USD | +242.4% | +20.1% | — | |
| LTM Mar 2026 | $48.5M USD | +262.3% | — | 134713.9% | |
| LTM Mar 2026 | $46.57M USD | +289.8% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $27.72M USD | -86.6% | — | — |
| LTM Mar 2026 | $6.68M USD | +141.4% | — | — | |
| LTM Mar 2026 | $2.28M USD | +363.2% | +743.9% | — | |
| LTM Dec 2025 | $1M USD | -185.5% | -61.2% | — | |
| LTM Mar 2026 | $897K USD | -94.3% | -72.4% | — | |
| LTM Mar 2026 | $221K USD | -101.5% | -2.2% | — | |
| Peer median (excluding NBP) | — | +141.4% | +8.9% | 134713.9% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (2.33B) | (2.51B) | (208.18M) | (362.72M) | (88.34M) |
| Depreciation & Amortization | 34.14M | 63.82M | 1.06M | 7.14M | 856K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 608.61M | 357.15M | 10.26M | (14.23M) | 5.97M |
| Change in Working Capital | 394.52M | 552.06M | (37.2M) | (20.52M) | 17.07M |
| Accounts Receivables | 97.42M | 33.08M | 0 | 0 | 0 |
| Inventory | (27.24M) | 27.24M | 0 | 0 | 0 |
| Accounts Payables | 107.85M | 0 | 0 | 0 | 0 |
| Other Working Capital | 216.49M | 491.75M | (37.2M) | (20.52M) | 17.07M |
| Other Non-Cash Items | 321.18M | 431.48M | 161.2M | 5.9M | 43.84M |
| Operating Cash Flow | (973.09M) | (1.1B) | (72.85M) | (384.42M) | (20.6M) |
| Capital Expenditures | (29.93M) | (45.83M) | (164.35K) | (350.34K) | (7K) |
| Acquisitions (Net) | (6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (10.17B) | (7.41B) | 0 | (1.79B) | (49.96M) |
| Sales of Investments | 9.48B | 7.91B | 0 | 801.66M | 154.89M |
| Other Investing Activities | 0 | 26K | (107.47M) | 452.53K | 47K |
| Investing Cash Flow | (727.21M) | 458.38M | (107.63M) | (992.42M) | 104.97M |
| Debt Repayment | 0 | 2.75M | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.91M |
| Common Stock Repurchased | 0 | (3.08M) | (8.66M) | (2.45M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 593.92M | 60.86M | 407.88K | 0 | (4.19M) |
| Financing Cash Flow | 593.92M | 42.36M | (8.25M) | (2.44M) | 57.73M |
| Effect of Forex Changes | (128.77M) | 389.2M | 36.89M | (327.04M) | 276K |
| Net Change in Cash | (1.24B) | (212.86M) | (151.58M) | (1.71B) | 142.37M |
| Free Cash Flow | (1B) | (1.15B) | (73.02M) | (384.77M) | (20.6M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.